key: cord-0916516-7w30k6tc
authors: Gandhi, Yashika; Mishra, Sujeet K.; Rawat, Hemant; Grewal, Jyotika; Kumar, Ravi; Shakya, Santosh K.; Jain, Vipin Kumar; Babu, G.; Singh, Arjun; Singh, Ravindra; Acharya, Rabinarayan; Kumar, Vijay
title: Phytomedicines Explored under In vitro and In silico Studies against Coronavirus: An Opportunity to Develop Traditional Medicines
date: 2022-05-02
journal: S Afr J Bot
DOI: 10.1016/j.sajb.2022.04.053
sha: 937c721a5134408971417fee1816554dfc29a8ec
doc_id: 916516
cord_uid: 7w30k6tc

The widespread COVID-19 pandemic, caused by novel coronavirus SARS-CoV-2, has emanated as one of the most life-threatening transmissible diseases. Currently, the repurposed drugs such as remdesivir, azithromycine, chloroquine, and hydroxychloroquine are being employed in the management of COVID-19 but their adverse effects are a matter of concern. In this regard, alternative treatment options i.e., traditional medicine, medicinal plants, and their phytochemicals, which exhibit significant therapeutic efficacy and show a low toxicity profile, are being explored. The current review aims at unraveling the promising medicinal plants, phytochemicals, and traditional medicines against SARS-CoV-2 to discover phytomedicines for the management of COVID-19 on the basis of their potent antiviral activities against coronaviruses, as demonstrated in various biochemical and computational chemical biology studies. The review consists of integrative and updated information on the potential traditional medicines against COVID-19 and will facilitate researchers to develop traditional medicines for the management of COVID-19.

The incessant COVID-19 (Coronavirus Disease) pandemic, caused by a novel coronavirus strain namely, severe acute respiratory syndrome-related coronavirus (SARS-CoV-2), has perturbed the entire human race globally since its inception in December 2019 (Ratten, 2020) . The number of cases infected with COVID-19 and reported deaths have been perpetually increasing to date due to its rapid transmission and high mortality rate (Zhu et al., 2019) . Presently, COVID-19 patients are being treated by providing symptomatic treatments including the use of repurposed antiviral drugs and by giving oxygen support. Since the pathophysiology of COVID-19 is complicated and no repurposed drug has provided a sure shot cure against the disease, various therapies targeting the therapeutic targets of the virus, systemic inflammation, and enhancement of the immune response would prove to be more fruitful for patients (Li et al., 2021) . The current uncontrolled surge in COVID-19 cases, consequent fatalities and a dearth of potent antiviral therapy devoid of detrimental effects against SARS-CoV-2 necessitate the integration of traditional medicinal systems with modern medicine Vellingiri et al., 2020) . Since time immemorial, traditional medicine, medicinal plants, and natural products have provided an indispensable cure against the majority of ailments. Herbal medicines have also exhibited remarkable potency against innumerable viruses including Coronaviruses, Influenza virus, Human immunodeficiency virus, Zika Virus with barely any deleterious effects (Akram et al., 2018; Das et al., 2021; Lee at al., 2018; Saxena et al., 2016) . The secondary metabolites derived from medicinal plants have also been reported to exhibit biological functions such as antiviral, anti-inflammatory, antifungal, antibacterial, antidiabetic, analgesic, and immunomodulatory activities (Das et al., 2021) . Since the emergence of the epidemic caused by SARS-CoV-2, various medicinal plants and phytochemicals have been examined for their therapeutic potential against β-coronavirus-associated diseases (Das et al., 2021; Jin et al., 2020; Li et al., 2021) . It has been reported that SARS-CoV and SARS-CoV-2 exhibit genomic homology and similarities in the pathophysiological processes therefore the effect of medicinal plants and traditional medicine on SARS-CoV may also assist in combat against COVID-19 (Li et al., 2021) . The aim of the current review is to provide comprehensive information on herbal flora, traditional medicine, and phytochemicals exhibiting antiviral activities that have been investigated via in silico, in vivo, in vitro, preclinical, clinical studies and have been found to be potent against coronavirus especially, SARS-CoV-2. 

The structural studies revealed that SARS-CoV-2 is a single-stranded, spherical, enveloped, positive-sense RNA virus with an approximate size of 125 nm and a genome size ranging from 27 kb to 32 kb (Vellingiri et al., 2020) . There are four major structural proteins present in SARS-CoV-2, namely nucleocapsid protein (N), membrane protein (M), an envelope protein (E), and spike protein (S) as represented in Fig. 1 . The nucleocapsid consists of a viral genome and has a shell of an envelope surrounding it. This envelope has M, S, and E structural proteins associated with it. The membrane protein is a transmembrane glycoprotein that aids the virus in developing capsid and structure assembly. The envelope protein is responsible for the virus packaging while the spike protein aids in the entry of the virus into host cells (Naqvi et al., 2020) . Although there is a similarity between the sequence homology of SARS-CoV and SARS-CoV-2, there is a difference in the transmission efficiencies of these two viruses and these contrast inefficiencies can be attributed to the difference in nucleotide sequences in spike protein and receptor binding domain (Tang et al., 2020) . In a study carried out by Gordon et. al. (2020) , 332 interactions have been identified between SARS-CoV-2 proteins and human proteins. 

The structural studies have revealed that there is a sequence homology between SARS-CoV and SARS-CoV-2 but an appreciable difference in their transmission potential and infection range has been observed due to the difference in nucleotide sequences (Belouzard et al., 2012) . Some of the major structural differences in SARS-CoV-2 as compared to SARS-CoV are longer 8b segments, shorter 3b segments, and absence of 8a segments along with a difference in Nsp-2 and -3 proteins (Vellingiri et al., 2020) . The main entry of SARS-CoV-2 into host cells is similar to that of SARS-CoV i.e., recognition and binding of S proteins to angiotensin-converting enzyme 2 (ACE2) receptor of host cells (Fig. 2) (Hoffmann et al., 2020; Zhou et al., 2020) . The Cryo-EM structure analysis revealed that SARS-CoV-2 exhibits a 10-to-20-fold higher affinity of S-protein to the human ACE2 receptor than that of SARS-CoV and thus produces more pathogenicity and has a higher infection transmission rate (Wrapp et al., 2020) . Therefore, the widespread COVID-19 disease is perceived to be more dangerous with no specific treatment. The finding of ACE2 as the receptor of SARS-CoV-2 also indicates that human organs with high ACE2 expression levels, such as lung alveolar epithelial cells and enterocytes of the small intestine, are potentially the target of SARS-CoV-2 (Zhou et al., 2020) . After binding, the fusion of virus particles with the host cell membrane takes place due to the conformational changes taking place in the spike protein. The process of fusion is dependent on two factors viz. proteolytic activation and pH acidification (Belouzard et al., 2012; Das et al., 2021) . Once fusion takes place, cleavage of fusion protein takes place to continue the process of infection. The S-protein is homotrimeric and each of its subunits has two domains; the receptor-binding domain (S1) and the membrane fusion domain (S2) that enables the entry of the virus into the host cell. The cleavage of S protein takes place by proteases into S1 and S2 domains that facilitate the entry of the virus into the host cell (Belouzard et al., 2012) . Proteases such as human airway trypsin-like protease and transmembrane protease serine family instigate the fusion of SARS-CoV-2. Some coronaviruses like SARS-CoV and MHV-2 do not require cleavage of S proteins to enter the host cells and can directly enter the host cells in the presence of exogenous proteases (Shulla et al., 2011) . After the process of fusion, the fusion protein enters the host cell which results in the cleavage of ACE-2. The cleavage of ACE-2 is responsible for the conversion of angiotensin I to angiotensin II that is a negative regulator of the renin-angiotensin pathway.

Also, the reduction of ACE-2 is accountable for respiration-related diseases (Li and De Clercq, 2020) . The subsequent step to the fusion of virus particles is the release of viral genome into the cytoplasm which further leads to the translation of viral polymerase namely, RNA-dependent RNA polymerase ( Fig. 2 ) (RdRp). Further, the replication and transcription of viral RNA takes place resulting in the translation of accessory and structural proteins of the virus (Zhou et al., 2021) . After the translation of viral protein into the host cell, numerous copies of the virus are transported by the host cell to the cell surface which further allows the virus to infect other cells (Li et al., 2021) . Once the SARS-CoV-2 has infected the host cells, a well-coordinated and prompt ingrained immune response is activated (Vabret et al., 2020) .

The pattern recognition receptor (PRR) on the membrane of the host cells recognizes pathogen-associated molecular pattern (PAMP) of the virus which is responsible for the activation of innate immune cells such as dendritic cells, neutrophils, macrophages, and monocytes to instigate the synthesis and secretion of inflammatory cytokines (Vabret et al., 2020) . In the course of viral infection, IL-6 and IL-1β, the prime pro-inflammatory cytokines that coordinate the systemic inflammation in infected individuals, facilitate inflammation in the alveoli and bronchi. The overproduction of cytokines and uncontrolled inflammatory responses are responsible for acute lung injury, respiratory disorders, the spread of infection and might contribute to the impaired immune system (Vellingiri et al., 2020) . Apart from lung injury and respiratory disorders, COVID-19 is considered to be a disease affecting multiple organs including the liver, heart, and kidney that might lead to multiple organ dysfunction as SARS-CoV-2 disperses to other crucial tissues and organs after the onset of initial infection in the respiratory system. This dispersion of SARS-CoV-2 to other organs activates a complex spectrum of pathophysiological changes and symptoms (Zaim et al., 2020) .

The identification of potent medicinal plants and phytochemicals is done on the basis of their capability to interfere with the pathogenesis of the virus and identifying their therapeutic targets (Pandey et al., 2020) . Since there are two crucial stages in the coronavirus pathogenesis i.e., entry of the virus to its host cells and its replication, the potential antiviral drug must be capable of interfering either with the entry of the virus into the host cell or with one or more stages of its replication (Fig. 3) (Jalali et al., 2021) . Some of the reported potential therapeutic targets of SARS-CoV-2 include ACE-2, 3-chymotrypsin-like protease (3CLpro), transmembrane protease serine 2 (TMPRSS2), papain-like protease (PLpro), RNAdependent RNA polymerase (RdRp), and S proteins (Hoffmann et al., 2020; Mani et al., 2020; Zhou et al., 2020) . Since the attachment of S-proteins of SARS-CoV-2 with ACE-2 receptor of the host cells is the entry pathway of the virus into the cell, it has been reported that ACE-2 could be one of the potential therapeutic targets as it can block the binding of the virus into the host cells (Zhang et al., 2020b) . In addition to ACE-2, TMPRSS2 is also accountable for the viral cell entry as it activates the S-protein of the virus by cleaving it into two subunits namely, S1 and S2 (Belouzard et al., 2012) . Both the subunits exhibit different functions as S1 binds with the surface receptor of the host cell while S2 aids in the fusion of viral cell and host cell (Belouzard et al., 2012) . In various studies, it has been communicated that the inactivation of TMPRSS2 could be responsible for the inhibition of viral infection (Hoffmann et al., 2020) .

RdRp, also known as Nsp12, is the vital protein present in coronavirus which is responsible for the replication of virus and transcription. RdRp binds with cofactors namely, nsp7 and nsp8 and produces viral genomic RNA (Kirchdoerfer and Ward, 2019). Main protease Nsp5, also called 3CLpro or Mpro, is auto-cleaved from the polyproteins and further cleaves the nsps at 11 sites, viz., nsp4-nsp16 which is a crucial step in the mechanism of viral infection (Snijder et al., 2016) . Since 3CLpro plays a crucial role in viral replication and transcription, it is regarded as one of the important therapeutic targets for COVID-19 (Khodadadi et al., 2020) . Papain-like protease (PLpro) is a polypeptide that is involved in the cleavage of the N terminal region of polyprotein which results in the formation of nsp1, nsp2, and nsp3 that are required for correction of viral replication (Wu et al., 2020c) . Cathepsin, a lysosomal protease, has an important role to play in cellular protein turnover (Zhou et al., 2016) .

Numerous studies have communicated that cathepsin B is involved in the life cycle of coronavirus and facilitates the viral entry into the cytoplasm through endosomes by undergoing fusion with viral envelope and endosomal membrane (Das et al., 2021) .

At present, no specific and effective treatment has been discovered for this novel coronavirus disease and infected patients are being treated on the basis of symptomatic treatment protocol (Khan and Al-Balushi, 2021) . The World Health Organisation (WHO) has recommended preventive measures like social distancing, use of face masks and sanitizers, washing hands properly, timely diagnosis, quarantine for infected people and symptom-based treatment to curb and contain the spread of this life-threatening virus and COVID-19 disease (Khan and Al-Balushi, 2021) . The uncontrolled transmission and soaring cases of morbidity and mortality due to this pandemic have put the development of effective vaccines and antiviral therapy into focus but the development of potential antiviral drugs against COVID-19 may take months or years and only a few vaccines have obtained the provisional license for their emergency use (Saggam et al., 2021) . Currently, the repurposed drugs such as antivirals (e.g., remdesivir), antibiotics (e.g., azithromycin), antimalarials (e.g., chloroquine and hydroxychloroquine), and immunomodulators (e.g., tocilizumab) are being employed in the management of COVID-19 but their adverse effects are a matter of concern (Saggam et al., 2021) . Therefore, in order to reduce the pressure on hospitals and healthcare infrastructure, there is a need to employ medicinal plants and traditional medicines as an alternative measure. Medicinal plants and natural products derived from them, which show a low toxicity profile, are economical and readily available, are considered to treat both principal and secondary aspects of disease in traditional medicine systems. There are innumerable medicinal plants that follow multi-component and multi-target approaches and could produce remarkable results in the prevention and management of COVID-19 (Li et al., 2021) . Since SARS-CoV-2 demonstrates homology with SARS-CoV in terms of epidemiology, genomic and its pathogenesis, the medicinal plants that are proven to be effective against SARS-CoV might aid in the management of COVID-19. The low toxicity and accessibility of medicinal plants and their phytochemicals targeting SARS-CoV-2 or the host targets could be a prospective approach for managing COVID-19 (Li et al., 2021) .

A plethora of evidence is available on the medicinal significance of various herbs and traditional medicines against coronaviruses including SARS CoV and MERS-CoV indicating their pharmacological activities (Das et al., 2021; Singh et al., 2021) . For instance, medicinal plants and herbal formulations belonging to traditional Chinese medicine (TCM) played an indispensable role in the prevention of SARS transmission (Ho et al., 2007; Yang et al., 2020) . During 2003, the Chinese government employed the Traditional Chinese Medicines (TCM) to treat SARS-CoV disease and it has been reported that TCM was successful against SARS-CoV owing to their immune-boosting actions (Yu et al., 2012) .

From the literature search, it has been comprehended that phytochemicals such as flavonoids, alkaloids, anthraquinones, stilbenes, essential oils, etc. exhibit antiviral activities against SARS-CoV-2 (Das et al., 2021; Jena et al. 2021) .

In an attempt to identify natural compounds associated with antiviral activities against SARS-CoV (summarized in Table 1 (leaves), and Lycoris radiata (Stem cortex) were found to be potent against SARS-CoV exhibiting 50% effective concentration (EC 50 ) values in the range of 2.4 to 88.2 µg/ml (Li et al., 2005) . In the study, Lycoris radiata was found to be the most potent against SARS-CoV and therefore its extract was further subjected to purification techniques to discover the molecule responsible for anti-coronavirus activities where an alkaloid namely, Lycorine (1), having EC 50 value of 15.7 µg/ml was isolated from the ethanolic extract of Lycoris radiata (EC 50 value 2.4 µg/ml) (Li et al., 2005) . Cheng et al. (2006) examined the antiviral activity of Saikosaponins (A, B 2 , C, D) (2-5) isolated from three plants namely Bupleurum spp., Heteromorpha spp., and Scrophularia scorodonia and found that the selected Saikosaponins were potent against the coronavirus strain HCoV-22E9. The EC 50 values of the Saikosaponins lie in the range of 1.7 to 19.9 µg/ml and Saikosaponin B 2 (3) was found to be most potent with an EC 50 value of 1.7 µg/ml.

The mode of action of Saikosaponin B 2 (3) against HCoV-22E9 strain was reported to be the inhibition of viral attachment and penetration stages (Cheng et al., 2006) . Several research groups have also investigated the antiviral activity of saikosaponins against other viruses like hepatitis B viru,. herpes simplex virus, HIV, and cytomegalovirus (Bahbah et al., 2006; Cheng et al., 2006) . Therefore, saponins are a class of interest among researchers to be explored for their therapeutic potential against COVID-19. The antiviral activity of saponins is attributed to their property to interact with viral envelope and capsid protein resulting in the disruption of viral particles and also, to their interaction with host cell membrane which leads to the inhibition of attachment of viral cell to the host cells which further prevents the fusion by coating the cell surface and minimizes the proliferation of infection (Das et al., 2021) . In a study on the antiviral activity of saponins, it has been reported that Quillaja saponaria extract consisting of triterpenoid saponins was found to be effective against HIV-1 and HIV-2 (Roner et al., 2007) . On similar lines, to explore the antiviral activities of saponins and triterpene saponin extracted from Anagallis arvensis exhibited antiviral activity against poliovirus and HSV1 (Amoros et al., 1987) . (Yu et al., 2012) .

In an in vitro study, performed by Wen et. al. (2007) , 226 phytochemicals were assessed for anti-SARS-CoV activities. Out of the selected 226 phytochemicals, 22 were found to be potent inhibitors and the phytochemicals namely, ferruginol (25), 8βhydroxyabieta-9(11),13-dien-12-one (26), and savinin (27) (present in Chamaecyparis obtuse var. formosana), 3β,12-diacetoxyabieta-6,8,11,13-tetraene (28), betulinic acid (29) (from Juniperus formosana), and 7β-hydroxydeoxycryptojaponol (30) (present in Cryptomeria japonica) were demonstrated to be the most potent phytochemicals against SARS-CoV-2. In the indicated study, the concentration of 22 screened-out phytochemicals required to inhibit 50% of Vero E6 cell proliferation (CC 50 ) and viral replication (EC 50 ) were calculated. The observed EC 50 values for SARS-CoV replication inhibition ranged from 0.63 to 1.57 µM.

The inhibitory activities of the 22 phytochemicals on SARS-CoV 3CLpro were investigated and it was concluded that only savinin (27) and betulinic acid (29) exhibited significant inhibition activity on 3CLpro (Wen et al., 2007) .

Tripterygium regelii and evaluated them for their SARS-CoV 3CLpro inhibitory activities.

The isolated terpenes namely, celastrol (31), pristimerin (32), tingenone (33), and iguesterin (34) exhibited appreciable SARS-CoV 3CLpro inhibitory activities displaying IC 50 values of 10.3, 5.5, 9.9, and 2.6 l µM, respectively (Ryu et al., 2010b) .

In an in vitro study conducted by Song et. al. (2014) , it has been manifested that the methanolic extract of Tribulus terrestris fruits exhibits potent SARS-CoV-PLpro inhibitory activity. In order to probe the phytochemicals responsible for the SARS-CoV-PLpro inhibitory activity of the extract, six cinnamic amides namely, N-trans-caffeoyltyramine (35) values ranging from 1 to 10 µg/ml (Ho et al., 2007) . Emodin (45), commonly found anthraquinone in Rheum and Polygonum is also responsible for the inhibition of the interaction between ACE2 and S-protein of SARS-CoV and therefore, it has been suggested in the study that Emodin (45) could be responsible for the anti-SARS-CoV activities (Ho et al., 2007) .

In literature, it has been reported that phytochemicals of Glycyrrhiza glabra are potent against SARS-CoV. The two major phytochemicals namely, glycyrrhizin (46) and glycyrrhizic acid (47) exhibit more potent antiviral activity against SARS-CoV (Cinatl et al., 2003; Hoever et al., 2005) . Further studies have revealed that the addition of 2-acetamido-β-D-glucopyranosylamine into the glycoside chain of glycyrrhizin (46) produced a ten-fold potency against SARS-CoV (Hoever et al., 2005) .

In an in vitro study carried out to evaluate the inhibitory activity of polyphenols derived from Broussonetia papyrifera, against 3CLpro and PLpro of SARS-CoV and MERS-CoV, Park et al. (2017) reported that the isolated compounds i.e., broussochalcone A (48), broussochalcone B (49), papyriflavonol A (50), 4-hydroxyisolonchocarpin (51), kazinol A (52), kazinol B (53), kazinol F (54), kazinol J (55) and broussoflavan A (56) are more potent against PLpro than against 3CLpro. In the study, papyriflavonol A (50) has been concluded to exhibit the greatest inhibitory activity against PLpro demonstrating an IC 50 value of 3.7 μM (Park et al., 2017) .

Withania somnifera is a well-renowned medicinal herb that is known to exhibit antiviral and immunomodulatory activities (Singh et al., 2021) . In literature, various researchers have examined the therapeutic potential of withanolides, the principal phytochemicals of Withania somnifera, against SARS-CoV-2 (Kumar et al., 2020c; Saggam et al., 2021) . Withanolides belong to the steroidal lactone terpenoid class of compounds and include withanolide A, B, and D, withaferin A, withanone, withanoside IV and V, withasomniferin A, sitoindoside IX and X, etc. (Saggam et al., 2021) . In an in vitro study carried out by Kumar et al. (2020c) , it has been revealed that withanone (57) downregulates mRNA of TMPRSS2 in MCF7 cells (Kumar et al., 2020c) .

The majority of studies mentioned in the review have been in vitro. The in vitro studies have been proven to be advantageous due to a number of reasons including reduction in variability of results, cost-effectiveness, and rapidity (Arora et al., 2012) . The major limitations of in vitro studies include variation in biokinetics parameters and application of results to human, owing to their lesser reliability as compared to in vivo studies (Saeidnia et al., 2015) . But since in vivo studies are cumbersome to carry out, screening of phytochemicals and medicinal plants on the basis of in vitro studies is appropriate and provide a roadmap for in vivo studies and further clinical studies.

Numerous research groups have carried out in silico investigations on various phytochemicals of different medicinal plants exhibiting antiviral activity by docking them as ligands against therapeutic targets in the pathogenesis of SARS CoV-2 in order to explore whether the screened phytochemicals can be employed as novel agents to control SARS-CoV-2 or not so that further in vitro and in vivo studies can be conducted on their therapeutic potency and efficacy (Sagar and Kumar, 2020; Shah et al., 2021a; Shah et al., 2021b; Thakkar et al., 2021; .

In an in silico study performed to examine and explore the anti-SARS-CoV-2 activities of 125 Chinese herbs, the interaction of major SARS-CoV-2 proteins involved in its entry and replication like PLpro, 3CLpro, and S-protein was investigated against the phytochemicals of the selected herbs . The preliminary step in the screening of the plants was the selection of phytochemicals proven to be effective against either SARS or MERS and their presence in the Traditional Chinese Medicine System Pharmacology Database. Further, Chinese herbal databases were searched to identify plants consisting of two or more selected phytochemicals followed by the network pharmacology analysis to predict the generally known in vivo effects of the screen out drugs. Since SARS-CoV-2 exhibits certain mutations in comparison to SARS-CoV and MERS-CoV, the screened phytochemicals might not be as efficacious as against the other two coronaviruses . In this study, it was revealed that herbs consisting of two or more compounds like Betulinic acid (29) Yang-reinforcing) and category F includes herbs for prevention namely, Fortunes boss fern rhizome (Warming interior) . In another in silico study, 1066 phytochemicals including 78 frequently used antiviral drugs were screened by using the 3CLpro, PLpro, and RNA polymerase, targets with the intention to provide a pathway to develop an antidote for SARS-CoV-2 (Wu et al., 2020b) . The structure of important phytochemicals 70-83 are mentioned under Table - (95) against four therapeutic targets of SARS CoV-2 involved in its attachment and replication via an in silico study. The study communicated that the efficacy of the selected phytochemicals is comparable to that of renowned antiviral drugs such as Remdesivir, Lopinavir and Favipiravir (Sagar and Kumar, 2020) .

A number of molecular docking studies have been carried out on the phytochemicals of Withaniasomnifera attributing to its antiviral and immunomodulatory activities in order to examine their binding affinity with therapeutic targets in the management of COVID-19 and their therapeutic potential against SARS-CoV-2 (Balkrishna et al., 2020; Kumar et al., 2020c) . In an in silico study carried out by Balkrishna et al., 2020 on withanone (57) , it has been reported that withanone blocks the entry of SARS-CoV-2 by interrupting the electrostatic interactions between the RBD and ACE2 (Balkrishna et al., 2020) . Kumar et al.,

2020c carried out an in silico study using a computational molecular docking tool and concluded that withanone (57) and withaferin A (96) block Mpro and TMPRSS2 enzyme which leads to inhibition in the viral entry and replication (Kumar et al., 2020c; Sharma and Deep, 2020) .

In one of the molecular docking analyses carried out by Borse et al., 2020, withacoagin (97) and withanolide B (98) have been predicted to exhibit higher binding affinity with viral S-protein and RdRp enzyme (Borse et al., 2020) . In another in silico investigation, withaferin A (96) is predicted to inhibit host receptor glucose-regulated protein 78 (GRP78) which is found to be upregulated in COVID-19 patients (Sudeep et al., 2020) .

Although an ample amount of in silico studies have been carried out on the potential of withanolides in SARS-CoV-2 viral inhibition, there is limited experimental and clinical data available on the efficacy of withanolides in the management of COVID-19. Therefore, there is a need to carry out comprehensive pharmaco-mechanistic studies and systematic experiments on withanolides to examine their potency as antiviral agents in COVID-19. Andrographis paniculata, also known as Kariyat, is a medicinal plant commonly harvested in India and is reported to exhibit antiviral activity (Singh et al., 2021) . Enmozhi et al. (2020) conducted an in silico study on andrographolide (104), an extract of Andrographis paniculata and discovered that fitted efficiently with the Mpro of SARS-CoV-2 virus thereby, inhibiting its pathogenesis (Enmozhi et al., 2020) . Andrographolide (104) scored high in the docking study and its docking affinity was established to be appreciably higher than the repurposed synthetic drugs used against SARS-CoV-2 like tideglusib and a combination of lopinavir, oseltamivir, and ritonavir. Andrographolide also demonstrated notably high druggability, solubility, permeability and target accuracy in the in silico study. It has also been reported that Andrographis paniculatainhibits the elevated levels of some of the molecules involved in the SARS-CoV mechanism including caspase-1, interleukin-1β and NOD-like receptor protein-3 (NLRP3) (Liu et al., 2020) .

Numerous virtual screening studies have demonstrated that a variety of flavonoids namely, kaempferol (64), mangiferin (105), amentoflavone, quercetin, isoquercetin, diosmin, hidrosmin, gallocatechin gallate exhibit strong binding affinities with Mpro enzyme, one of the most prominent therapeutic targets, and therefore, these flavonoids could be employed to treat COVID-19 patients (Anand et al., 2021; Das et al., 2021; Umar et al., 2021) . Quercetin (67), a flavonoid present in fruits and vegetables, is reported to exhibit antiviral properties in numerous studies (Harwood et al., 2007) . The co-administration of quercetin and vitamin C is disclosed to exert a synergistic effect in treating COVID-19 patients and this can be attributed to the synergistic antiviral, immunomodulatory and antioxidant activities along with the potential of ascorbate to recycle quercetin which leads to an increase in efficacy of quercetin against SARS-CoV-2 (ColungaBiancatelli et al., 2020). On the basis of the structural features of kaempferol (63), it is reported to exhibit greater binding stability with the N3 site in Mpro of SARS-CoV-2 (Owis et al., 2020) . Some of the flavonoids including myricetin, hesperetin and caflanone demonstrate high binding affinities with the ACE-2 receptor which is responsible for viral entry into the host cells (Ngwa et al., 2020) . The binding affinities of catechin (106) It has also been demonstrated in numerous virtual screening studies that stilbenes disrupt the interface of spike protein and ACE-2 receptor complex resulting in the inhibition of complex formed between spike protein and ACE-2 receptor which further blocks the entry of viral cell into the host cell. There are certain stilbenes namely, piceatannol (109) and resveratrol (110) that have a higher binding affinity to the spike protein and ACE-2 complex whereas stilbenes such as pterostilbene, pinosylvin and trans-resveratrol also exhibit antiviral activity but have comparatively lower binding affinity to this complex (Wahedi et al., 2021) .

The results for the application of phytochemicals against SARS-CoV-2 carried out by in silico studies the results might not always be consistent due to the significant differences in the cellular environment and the one that created in in silico studies. Therefore, rigorous in vitro and in vivo studies along with the clinical trials need to be carried out in order to corroborate these predictions and comprehend their role in the management of COVID-19.

The present scenario of the COVID-19 pandemic is an arduous challenge to the whole healthcare system since no well-established treatment protocol is available for the disease.

The insufficiency of current antiviral therapy employed in the management of COVID-19 has compelled the researchers to explore therapeutic alternatives in order to provide long-term preventative and curative measures against the deadly pandemic (Patel et al., 2021) . China has used TCM to treat the patients infected with SARS-CoV-2 where TCM in combination with allopathic drugs were administered to more than 85% of patients infected from SARS-CoV-2 (Jin et al., 2020). The National Health Commission of China has also outlined that TCM was found to be potent in more than 60,000 COVID-19 cases (National Health Commission of the People's Republic of China, 2020). The inhibition effects of a herbal formulation named Shuanghuanglian (oral liquid) against the SARS-CoV-2 have been evaluated in a combined investigation performed by Wuhan Institute of Virology and Shanghai Institute of Materia Medica. The presence of phytochemicals like forsythin, chlorogenic acid, and baicalin, in Shuanghuanglian, has shown convincing inhibitory effects against the wide range of viruses and bacteria (Li, 2002; Lu et al., 2000) . Shuanghuanglian is an immunomodulator and antiviral that can reduce the inflammation caused by viruses and bacteria (Chen et al., 2002) . Another Chinese herbal formulation used against the SARS-CoV-2 was Lianhuaqingwen (capsules) that demonstrate the same medicinal properties (antiviral and anti-inflammatory) as that of Shuanghuanglian (Ding et al., 2017) . It has been reported that Lianhuaqingwen significantly inhibits SARS-CoV-2 replication in Vero E6 cells and markedly reduces the production of pro-inflammatory cytokines (IL-6, TNF-α, CXCL-10/IP-10 and CCL-2/MCP-1) at the mRNA levels (Runfeng et al., 2020) On similar lines, the Indian traditional medicine system encompassing Ayurveda, Yoga, Naturopathy, Unani, Siddha, Sowa-Rigpa, and Homeopathy (AYUSH), which is more than 5000 years old and well-documented system, consists of ample traditional formulations and is anticipated to exhibit more satisfactory results against COVID-19 than any other Samshamani vati, also renowned as Guduchighanavati, is an ayurvedic formulation prepared from an aqueous extract of Tinospora cordifolia which is reported to be an immunomodulator that exhibits anti-inflammatory and antipyretic activity due to the synergistic effect of various phytochemicals (Patgiri et al., 2014) . AgasthavaHareetaki, consisting of more than fifteen medicinal plants, is also being employed in the management of COVID-19 symptoms as its ingredients exhibit antiviral, immunomodulatory, antiinflammatory and anti-asthmatic activities ).

The Unani system of medicine, also called Greco-Arab Medicine, is based on the concept of four conditions of living (hot, frosty, sodden and dry) and four humors of Hippocratic hypothesis viz., mucus, blood, yellow bile and dark bile .

including Triyaq-e-Araba, Roghan-e-Baboona, Khamira-e-Banafsha, etc. from time to time for the management of COVID-19 symptoms . Triyaq-e-Araba, one of the foremost Unani formulations, comprises Bergenia ciliata (stem), Laurus nobilis (berries), Commiphoramyrrha and Aristolochia indica (root) and is reported to exhibit remarkable antiviral activity against SARS-CoV (Loizzo et al., 2008) . Roghan-e-Baboona, an Unani remedy, consists of flowers of Matricaria chamomilla and is employed as an antiasthmatic and is utilized to treat inflammatory complaints because of the potency of M. chamomilla flowers against sore throat (Kyokong et al., 2002) . Khamira-e-Banafsha, a semi-solid Unani formulation, consists of decoction of flowers of Viola odorata as a principal ingredient and is widely used to treat acute respiratory ailments. Another significant Unani polyherbal formulation, Sharbat-e-Sadar, comprising Trachyspermum ammi as a chief ingredient, is commonly used to treat acute respiratory diseases . Roy et al. (2015) have reported that Trachyspermum ammi neutralizes antibodies for the Japanese encephalitis virus (Roy et al., 2015) . Asgandh Safoof has also been recommended in the Unani system of medicine as the root powder of Asgand (Withania somnifera) is reported to exhibit immunomodulatory activity and its extract enhances CD4+ and CD8+ counts and improves blood profile, especially platelet and WBC counts (Agarwal et al., 1999) . The aqueous suspension of Withania somnifera disturbs the binding between the ACE2 receptor and host viral S-protein binding domain and thus prevents the viral entry into the host cell (Balkrishna, et al., 2020; Kumar et al., 2020c) . 

In the present review, various medicinal plants, traditional medicines and phytochemicals that 

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors declare no conflict of interest.

Enmozhi, S. K., Raja, K., Sebastine, I., Joseph, J., 2020. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach. Journal of Biomolecular (We n et al., 2007 ) 3β, 12-diacetoxyabieta-6,8,11,13-tetraene (28) 

Studies on immunomodulatory activity of Withaniasomnifera (Ashwagandha) extracts in experimental immune inflammation

Indian Medicinal Plants and Formulations and Their Potential Against COVID-19-Preclinical and Clinical Research

Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: A systematic review

In vitro antiviral activity of a saponin from Anagallis arvensis, Primulaceae, against herpes simplex virus and poliovirus

Medicinal plants, phytochemicals, and herbs to combat viral pathogens including sars-cov-2

Nanotoxicology and in vitro studies: The need of the hour

Purposing Saikosaponins for the treatment of COVID-19

Withanone from Withaniasomnifera May Inhibit Novel Coronavirus (COVID-19) Entry by Disrupting Interactions between Viral S-Protein Receptor Binding Domain and Host ACE2 Receptor

Mechanisms of coronavirus cell entry mediated by the viral spike protein

Ayurveda botanicals in COVID-19 management: An in silico-multitarget approach

Effects of Shuanghuanglian and Qingkailing, two multi-components of traditional Chinese medicinal preparations, on human leukocyte function

Antiviral effects of saikosaponins on human coronavirus 229E in vitro

Glycyrrhizin, an active component of liquorice roots, and replication of SARSassociated coronavirus

Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19)

Origin and evolution of pathogenic coronaviruses

Role of phytoconstituents in the management of COVID-19

The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function

Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19)

Structural genomics approach. Biochimica et Biophysica Acta -Molecular Basis of Disease 1866, 165878

Potential of flavonoid-inspired phytomedicines against COVID-19

Molecular docking reveals the potential of Salvadora persica flavonoids to inhibit COVID-19 virus main protease

Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements

Dieckol, a SARS-CoV 3CLpro inhibitor

Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV

Evaluation of polyphenols from Broussonetiapapyrifera as coronavirus protease inhibitors

Anti-inflammatory activity of Guduchi Ghana (aqueous extract of Tinospora Cordifolia Miers

Therapeutic opportunities of edible antiviral plants for COVID-19

Antiviral activity obtained from aqueous extracts of the Chilean soapbark tree (Quillajasaponaria Molina)

Evaluation of antiviral activity of essential oil of Trachyspermum Ammi against Japanese encephalitis virus

Lianhuaqingwen exerts anti-viral and antiinflammatory activity against novel coronavirus (SARS-CoV-2)

Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition

SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii

From in vivo Experiments to in vivo and Clinical Studies; Pros and Cons

Efficacy of natural compounds from Tinospora cordifolia against SARS-CoV-2 protease, surface glycoprotein and RNA polymerase. Virology 1-10

Withaniasomnifera (L.) Dunal: Opportunity for Clinical Repurposing in COVID-19 Management

Zika virus outbreak: an overview of the experimental therapeutics and treatment

Prospecting for Cressacretica to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2

Exploring the active constituents of Oroxylum indicum in intervention of novel coronavirus (COVID-19) based on molecular docking method

In-silico drug repurposing for targeting SARS-CoV-2 main protease (Mpro)

A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry

Promising traditional Indian medicinal plants for the management of novel Coronavirus disease: A systematic review

The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing

Papain-like protease (PLpro) inhibitory effects of cinnamic amides from Tribulus terrestris fruits

Molecular docking analysis of Withaferin A from Withaniasomnifera with the Glucose regulated protein 78 (GRP78) in comparison with the COVID-19 main protease

On the origin and continuing evolution of SARS-CoV-2

Magical bullets from an indigenous Indian medicinal plant Tinospora cordifolia: An in silico approach for the antidote of SARS-CoV-2

In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from selected African plants

COVID-19: A promising cure for the global panic

Stilbene-based natural compounds as promising drug candidates against COVID-19

Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus

World Health Organization

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

An Update on Current Therapeutic Drugs Treating COVID-19

Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): A review and perspective

Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13

COVID-19 and Multiorgan Response

In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)

Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies

A Novel Coronavirus from Patients with Pneumonia in China

Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection

Sciences, New Delhi -110058, India are highly acknowledged for the facilities like library and internet provided to compile this study.